Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741871 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
A Phase 1 study of B-cell Lymphoma and Hodgkin's Lymphoma, sponsored by S*BIO.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00741871: Completed Phase 1 study of B-cell Lymphoma and Hodgkin's Lymphoma, sponsored by S*BIO.
NCT00741871 is a Phase 1 study of B-cell Lymphoma and Hodgkin's Lymphoma that has completed, run by S*BIO. The registered enrollment target is 35 participants, below the 89-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00741871, a Phase 1 study of B-cell Lymphoma and Hodgkin's Lymphoma, has completed, sponsored by S*BIO.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
Conditions Studied
Interventions
- DRUG SB1518
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
What the finished NCT00741871 record still lists
NCT00741871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 89-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SB1518 is the first listed.
NCT00741871 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00741871 about?
NCT00741871 is a clinical study titled "A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies". This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
What is the current status of trial NCT00741871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-07. Estimated completion is 2011-10.
What conditions does trial NCT00741871 study?
This clinical trial studies the following conditions: B-cell Lymphoma, Hodgkin's Lymphoma, Lymphoma, Malignant.
What interventions are being tested in trial NCT00741871?
The interventions under investigation include: SB1518 (DRUG).
Who is sponsoring clinical trial NCT00741871?
This trial is sponsored by S*BIO, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00741871 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00741871's enrollment target sits among peer trials
35 25th of 38 higher than 14 of 38 other B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia